Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
© 2022 The Author(s). Published by S. Karger AG, Basel..
BACKGROUND: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems.
SUMMARY: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications.
KEY MESSAGES: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA's analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Obesity facts - 16(2023), 2 vom: 31., Seite 149-163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yazıcı, Dilek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
89750-14-1 |
|---|
| Anmerkungen: |
Date Completed 16.03.2023 Date Revised 25.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000526808 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348634935 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348634935 | ||
| 003 | DE-627 | ||
| 005 | 20231226040727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000526808 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348634935 | ||
| 035 | |a (NLM)36349778 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yazıcı, Dilek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.03.2023 | ||
| 500 | |a Date Revised 25.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Author(s). Published by S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems | ||
| 520 | |a SUMMARY: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications | ||
| 520 | |a KEY MESSAGES: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA's analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Complications | |
| 650 | 4 | |a Glucagon-like peptide-1 receptor analog | |
| 650 | 4 | |a Obesity | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Yapıcı Eser, Hale |e verfasserin |4 aut | |
| 700 | 1 | |a Kıyıcı, Sinem |e verfasserin |4 aut | |
| 700 | 1 | |a Sancak, Seda |e verfasserin |4 aut | |
| 700 | 1 | |a Sezer, Havva |e verfasserin |4 aut | |
| 700 | 1 | |a Uygur, Melin |e verfasserin |4 aut | |
| 700 | 1 | |a Yumuk, Volkan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obesity facts |d 2008 |g 16(2023), 2 vom: 31., Seite 149-163 |w (DE-627)NLM194168867 |x 1662-4033 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:2 |g day:31 |g pages:149-163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000526808 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 2 |b 31 |h 149-163 | ||